UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

Clinical cancer research, 2011-11, Vol.17 (21), p.6847-6857

2011

Volltextzugriff (PDF)

Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers

Cancers, 2022-01, Vol.14 (3), p.571

Kyte, Jon Amund

2022

Volltextzugriff (PDF)

Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma

International journal of cancer, 2014-01, Vol.134 (1), p.102-113

2014

Volltextzugriff (PDF)

Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers

International journal of molecular sciences, 2024-01, Vol.25 (1), p.586

2024

Volltextzugriff (PDF)

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors

Cancer immunology research, 2018-04, Vol.6 (4), p.467-480

2018

Volltextzugriff (PDF)

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

Frontiers in immunology, 2020-11, Vol.11, p.572172-572172

2020

Volltextzugriff (PDF)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy

Advances in radiation oncology, 2018-04, Vol.3 (2), p.130-138

2018

Volltextzugriff (PDF)

Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform

Cancers, 2022-10, Vol.14 (19), p.4859

2022

Volltextzugriff (PDF)

Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy

Biomedicines, 2023-02, Vol.11 (2), p.459

2023

Volltextzugriff (PDF)

Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer

Molecular therapy. Oncolytics, 2022-09, Vol.26, p.189-206

2022

Volltextzugriff (PDF)

Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics

Oncoimmunology, 2019-02, Vol.8 (2), p.e1537691-e1537691

2019

Volltextzugriff (PDF)

Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation

NPJ breast cancer, 2024-04, Vol.10 (1), p.30-30, Article 30

2024

Volltextzugriff (PDF)

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Journal for immunotherapy of cancer, 2024-01, Vol.12 (1), p.e007990

2024

Volltextzugriff (PDF)

Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab

Oncoimmunology, 2018-11, Vol.7 (11), p.e1457598-e1457598

2018

Volltextzugriff (PDF)

Cancer vaccination with telomerase peptide GV1001

Expert opinion on investigational drugs, 2009-05, Vol.18 (5), p.687-694

Kyte, Jon Amund

2009

Volltextzugriff (PDF)

Genforandringer som egner seg for målrettet kreftbehandling

Tidsskrift for den Norske Lægeforening, 2023-06

2023

Volltextzugriff (PDF)

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment

Nature communications, 2019-12, Vol.10 (1), p.5499-14, Article 5499

2019

Volltextzugriff (PDF)

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Nature medicine, 2022-12, Vol.28 (12), p.2573-2583

2022

Volltextzugriff (PDF)

Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency

Methods in molecular biology (Clifton, N.J.), 2020-01, Vol.2115, p.327

2020

Volltextzugriff (PDF)

Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients

Clinical cancer research, 2011-07, Vol.17 (13), p.4568-4580

2011

Volltextzugriff (PDF)

Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination

Cancer Immunology, Immunotherapy, 2015-12, Vol.64 (12), p.1609-1621

2015

Volltextzugriff (PDF)

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular oncology, 2024-07

2024

Volltextzugriff (PDF)

Abstract 3190: Standardization and clinical implementation of liquid biopsy assays - IMI's CANCER-ID

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3190-3190

2019

Volltextzugriff (PDF)

Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells

Oncoimmunology, 2016-11, Vol.5 (11), p.e1232237-e1232237

2016

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(53)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers

Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma

Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy

Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform

Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy

Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer

Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics

Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab

Cancer vaccination with telomerase peptide GV1001

Genforandringer som egner seg for målrettet kreftbehandling

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency

Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients

Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Abstract 3190: Standardization and clinical implementation of liquid biopsy assays - IMI's CANCER-ID

Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells

IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results

Suchergebnisse filtern